The epidemiologic parameters for COVID-19: A Systematic Review and Meta-Analysis
================================================================================

* Neda Izadi
* Niloufar Taherpour
* Yaser Mokhayeri
* Sahar Sotoodeh Ghorbani
* Khaled Rahmani
* Seyed Saeed Hashemi Nazari

## Abstract

**Introduction** The World Health Organization (WHO) declared the outbreak to be a public health emergency and international concern and recognized it as a pandemic. The aim of this study was to estimate the epidemiologic parameters of novel coronavirus (COVID-19) pandemic for clinical and epidemiological help.

**Methods** Four electronic databases including Web of Science, Medline (PubMed), Scopus and Google Scholar were searched for literature published from early December 2019 up to 23 March 2020. The “*metan*” command was used to perform a fixed or random effects analysis. Cumulative meta-analysis was performed using the “*metacum*” command.

**Results** Totally 76 observational studies were included in the analysis. The pooled estimate for R was 2.99 (95% CI: 2.71-3.27) for COVID-19. The overall R was 3.23, 1.19, 3.6 and 2.35 for China, Singapore, Iran and Japan, respectively. The overall Serial Interval, doubling time, incubation period were 4.45, 4.14 and 4.24 days for COVID-19. In addition, the overall estimation for growth rate and case fatality rate for COVID-19 were 0.38% and 3.29%, respectively.

**Conclusion** Calculating the pooled estimate of the epidemiological parameters of COVID-19 as an emerging disease, could reveal epidemiological features of the disease that consequently pave the way for health policy makers to think more about control strategies.

Keywords
*   Epidemiologic Parameters
*   R
*   Serial Interval
*   Doubling Time
*   Case Fatality Rate;COVID-19

## Introduction

Coronaviruses are a group of RNA viruses that cause diseases among humans and animals (1). The latest of coronavirus types as a novel coronavirus that was named severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) or COVID-19 occurred in Wuhan, China in December 2019 with a human outbreak (2).

The World Health Organization (WHO) declared the outbreak to be a public health emergency and international concern and recognized it as a pandemic on 11 March 2020 (3). COVID-19 has widely spread in the world and is prevalent in different countries such as China, Italy, United states, France, Spain, Iran and Germany with 2,833,697 cases and 197,354 deaths and 807,469 recovered until 24 April in the whole world (4). The main rout of transmission of COVID-19 is based on human-to-human transmission via either respiratory droplets, saliva or close contacts with infected people or aerosol generation procedures during clinical care of COVID-19 patients (5).

Most COVID-19 infected people (80.9%) are with mild to moderate respiratory syndromes, old people or patients with underlying diseases such as diabetes, cardiovascular disease, cancer, immune deficiency and respiratory disease are more at risk to develop sever (13.8%) and critical (4.7%) disease (6,7).

Knowledge regarding epidemiological characteristics and parameters of the infectious diseases such as, incubation period (time from exposure to the agent until the first symptoms develop), serial interval (duration between symptom onset of a primary case and symptom onset of its secondary cases), basic reproduction number (R) (the transmission potential of a disease) and other epidemiologic parameters is important for modelling and estimation of epidemic trends and also implementation and evaluation of preventive procedures (8–11).

About COVID-19 pandemic parameters, there are many reports from different countries in the world. For example, about 25.6 % to 51.7% of patients have been reported to be asymptomatic or with mild symptoms (12) and 25-30% of them have been admitted to ICU for medical care (13). Case-fatality rate was reported in China and other countries among old patients 6% (4-11% ranges) and 2.3 % in all ages (13,14). Furthermore, the median incubation period was reported as 5-6 days (2-14 ranges) from WHO while, in China incubation period was reported up to 24 days (15,16). Also, according to the different mathematical models, R was reported about 6.47 (1.66-10 ranges) in China, 2.6 in South-Korea and 4.7 in Iran (17,18,19).

Thus, according to the reports from different countries about epidemiological characteristics of COVID-19 pandemic, different methods and different values of parameters have been observed. So, for efficient estimation and forecasting of disease spreading, we need acceptable and real values of each parameter. The present study was conducted to provide a systematic assessment and estimation of parameters related to COVID-19. This evaluation will help researchers with better prediction and estimation of current epidemic trends.

## Method

The current study is a systematic review and meta-analysis to determine the epidemiologic parameters for COVID-19.

### Search Strategy

To find relevant studies, a comprehensive literature search of the Web of Science, Medline (Pubmed), Scopus and Google Scholar was performed for observational studies published electronically from early December 2019 up to 23 March 2020.

Two researchers independently searched studies. In search strategy, English keywords and probable combination of them were used. The keywords included “novel coronavirus” ، “2019-noCov”، “COVID-19”، “basic reproduction number”، “serial interval”̜ “incubation period” “،doubling time”، “growth rate”̜ “case-fatality rate” ̜“mortality rate”، “onset of symptom to hospitalization”. The Boolean operators (‘OR ‘and ‘AND’) were used for combination of keywords. The search strategy was as follows:

**Keywords:** (novel coronavirus OR 2019-nCov OR COVID-19) AND (basic reproduction number OR basic reproductive rate) OR (case fatality rate OR case fatality ratio) OR mortality rate OR doubling time OR growth rate OR incubation period OR onset of symptom to hospitalization.

### Study Selection

Consistent with PRISMA guidelines, the standard meta-analysis techniques, we included studies. All of the extracted articles independently were screened by two researchers. Abstract and full text of the articles were reviewed and duplicated studies were excluded and then relevant articles were selected for data extraction.

### Study inclusion and exclusion criteria

All epidemiological studies designs (observational studies) including peer reviewed or not peer reviewed articles that provided the epidemiologic parameters of interest regarding the novel corona virus were included. In addition, irrelevant studies, letters and news and studies that didn’t report epidemiologic parameters were excluded.

### Screening and Data extraction

All articles were reviewed independently by four researchers and information was extracted using designed checklist (**Appendix 1**). Extracted items were name of the first author, years and month of article published, duration of the study, location of study conduction, type of parameters, point estimate or mean/median and its confidence interval for epidemiological parameters and review status of articles (peer-reviewed or not).

### Quality assessment of studies

To assess the quality of included the peer-reviewed and not peer reviewed articles, we used the STROBE quality assessment scale for observational studies. We assessed the quality of all studies and finally, studies with high and medium quality were included in the analyses.

### Statistical analysis

The “metan” command was used to apply a fixed or random effects model based on Cochran’s Q-test results or a large Higgins and Thompson’s I2 value. Forest plots were used for graphical description of the results. Also, the “metacum” command was used for cumulative meta-analysis to determine trend of basic reproductive number (R).

In studies that mortality rate was reported, because of the denominator was confirmed cases, it was considered a case fatality rate (CFR). In addition, for studies that reported the median and interquartile range (IQR), the median was considered equivalent to the mean and the IQR was converted to standard deviation using the “IQR/1.35” formula. Stata 14 was used for all statistical analyses.

## Results

Having assessed the quality of relevant studies, 76 observational studies up to 23 March, 2020 were included in this study (**Follow diagram**). The majority of studies were done in Wuhan, China. Detailed information of the eligible studies and their characteristics has been shown in **Appendix 1** (12,17,18,20–92).

*   - **The overall basic reproductive number (**R**) by country and peer review status**
    
    **Total:** The overall R was 2.99 (95% CI: 2.71-3.27) for COVID-19 (**Table 1**).
    
    **Country:** The overall R was 3.23, 1.19, 3.6 and 2.35 for China, Singapore, Iran and Japan, respectively (**Table 1**).
    
    **Peer review status:** The overall R was 2.75 and 3.08 for peer reviewed and not peer reviewed articles, respectively (**Table 1**).

*   - **The overall serial interval (SI) by country and peer review status**
    
    **Total:** The overall SI was 4.45 days (95% CI: 4.03-4.87) for COVID-19.
    
    **Country:** Using random effect model, the overall SI was 4.46 and 4.64 days for China and Singapore, respectively (**Error! Reference source not found**.).
    
    **Peer review status:** The overall SI was 5.3 and 4.39 days for peer reviewed and not peer reviewed articles, respectively (**Error! Reference source not found.2**).

*   - **The overall doubling time by peer review status**
    
    **Total:** The overall doubling time was 4.14 days (95% CI: 2.67-5.62) for COVID-19.
    
    **Peer review status:** The overall doubling time was 3.33 and 4.64 days for peer reviewed and not peer reviewed articles, respectively (**Error! Reference source not found.3**).

*   - **The overall incubation period by peer review status**
    
    **Total:** The overall incubation period was 4.24 days (95% CI: 3.03-5.44) for COVID-19.
    
    **Peer review status:** The overall incubation period was 4.03 and 5.82 days for peer reviewed and not peer reviewed articles, respectively (**Table 1**).

*   - **The overall estimation for other epidemiologic parameters**
    
    The overall estimation for growth rate and case fatality rate for COVID-19 were 0.38% and 3.29%, respectively (**Table 1 & Fig 4**). In addition, the overall time from symptom onset to hospitalization was 5.09 days for COVID-19 (**Table 1**).

*   - **The trend of** R **for COVID-19**
    
    Based on the cumulative meta-analysis, the trend of R had been increasing at first and, then, decreasing in March.

![Figure1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088385/F1.medium.gif)

[Figure1](http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385/F1)

**Flow diagram of the study selection process and including publications for the epidemiologic parameters for COVID-19**

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088385/F2.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385/F2)

Figure 1. The overall serial interval (SI) for COVID-19 by country

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088385/F3.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385/F3)

Figure 2. The overall serial interval (SI) for COVID-19 by peer review status

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088385/F4.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385/F4)

Figure 3. The overall doubling time for COVID-19 by peer review status

![Figure 4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088385/F5.medium.gif)

[Figure 4.](http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385/F5)

Figure 4. The overall case fatality rate (CRF) for COVID-19

View this table:
[Table 1.](http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088385/T1)

Table 1. The overall estimation of epidemiologic parameters for COVID-19

## Discussion

In this secondary analysis, we aimed to calculate the pooled estimate of some epidemiological parameters of COVID-19 namely basic reproductive number (R), serial interval, doubling time, incubation period, growth rate, case fatality rate (CFR), and time from symptom onset to hospitalization. Overall, the estimates were 2.99, 4.45 days, 4.14 days, 4.24 days, 0.38%, 3.29%, and 5.09 days, in the same order. Considering urgent issues in pandemic situation, peers have not reviewed some published papers. Therefore, we tried to calculate the pooled parameters by peer review status.

It should be noted that, R variations to some extent might be due to different methods calculations including exponential growth method, maximum likelihood, and Bayesian time-dependent method (93–95).

According to our results the pooled estimate of CFR 3.29% (95% CI: 2.78-3.81) is lower than SARS-CoV(96) and MERS-CoV (97). Health control policies, medical standard, and detection rate could affect CFR (35). Moreover, CFR estimate in the early phase of the epidemic might be biased (overestimated). Usually in the early phase, some subclinical cases and patients with mild symptoms may not be detected (detection bias) (98,99).

Pooled estimate of incubation period using 22 studies was 4.24 days (95% CI: 3.03, 5.44). Valid and precise estimate of incubation period has a pivotal role for duration of quarantine (50). In fact, knowledge about incubation period is useful for surveillance and control approaches, also modeling and monitoring activities (100).

Our estimate for overall doubling time-time for a given quantity to double in size or number at a constant growth rate was 4.14 days (95% CI: 2.67, 5.62). The doubling time has an important implication for predicting epidemic. Generally, social distancing, quarantine, and active surveillance are needed to reduce transmission and consequently extend the doubling time (101). Moreover, the authors tried to estimate pooled measures for growth rate and serial interval. These two epidemiological parameters are used to estimate reproduction number (102).

As a limitation, all 76 studies (except for one, Mirjam E Kretzschmar et al) (103) have been conducted in Asia, particularly in Wuhan, China. Some epidemiological parameters in Europe, Africa, and America could be different based on control strategies. Hence, distribution of these epidemiological parameters could be more globally. Future studies to calculate more generalized pooled estimates, using studies all over the world, would be recommended.

## Conclusions

Calculating the pooled estimate of the epidemiological parameters of COVID-19 as an emerging disease, could reveal epidemiological features of the disease that consequently pave the way for health policy makers to think more about control strategies.

## Data Availability

The data of this study are available in appendix file

## Funding

This study was supported by School of Public Health and Safety, Shahid Beheshti University of Medical Sciences grant number 23149. The funding agency did not play any role in the planning, conduct, and reporting or in the decision to submit the paper for publication.

## Competing interests

The authors declare that they have no competing interests.

## Acknowledgment

We would like to appreciate all those researchers who helped us to conduct this study.

*   Received May 2, 2020.
*   Revision received May 2, 2020.
*   Accepted May 6, 2020.


*   © 2020, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Reusken CBEM, Raj VS, Koopmans MP, Haagmans BL. Cross host transmission in the emergence of MERS coronavirus. Current Opinion in Virology. 2016; 16: 55–62.
    
    

2.  2.Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. The Lancet Public Health. 2020. doi: 10.1016/S2468-2667(20)30073-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2468-2667(20)30073-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32220655&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

3.  3.Coronavirus disease (COVID-19) outbreak. 2020. Available at: [https://www.who.int/westernpacific/emergencies/covid-19](https://www.who.int/westernpacific/emergencies/covid-19) Access Apr, 2020.
    
    

4.  4.COVID-19 Coronavirus Pandemic. 2020. Available at: [https://www.worldometers.info/coronavirus/#countries](https://www.worldometers.info/coronavirus/#countries) Access Apr, 2020.
    
    

5.  5.Overview of coronavirus. 2020. Available at: [https://www.who.int/health-topics/coronavirus#tab=tab\_1](https://www.who.int/health-topics/coronavirus#tab=tab_1) Access Apr, 2020.
    
    

6.  6.Coronavirus disease 2019 (COVID-19) Situation Report—66. 2020. Available at: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-66-covid-19.pdf?sfvrsn=9e5b8b48_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200326-sitrep-66-covid-19.pdf?sfvrsn=9e5b8b48_2) Access Apr,2020.
    
    

7.  7.Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020. Available at: [https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf) Access Mar, 2020.
    
    

8.  8.Berhe H.W, Makinde O.D, Theuri D.M. Parameter Estimation and Sensitivity Analysis of Dysentery Diarrhea Epidemic Model. J. Appl. Math. 2019 (2019). Article ID 8465747. [https://doi.org/10.1155/2019/8465747](https://doi.org/10.1155/2019/8465747)
    
    

9.  9.Incubation period. 2020. Available at: [https://www.cdc.gov/training/QuickLearns/exposure/2.html](https://www.cdc.gov/training/QuickLearns/exposure/2.html) Access Apr,2020.
    
    

10. 10.Vink MA, Bootsma MC, Wallinga J. Serial intervals of respiratory infectious diseases: a systematic review and analysis. American journal of epidemiology. 2014 Nov 1;180(9):865–75. PubMed PMID: 25294601. Epub 2014/10/09. eng.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/aje/kwu209&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25294601&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000344600900001&link_type=ISI) 

11. 11.Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the Basic Reproduction Number (R0). Emerg Infect Dis. 2019;25(1):1–4. doi:10.3201/eid2501.171901
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3201/eid2501.171901&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30560777&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

12. 12.Zhao S, Cao P, Gao D, Zhuang Z, Chong M, Cai Y, et al. Modelling the coronavirus disease (COVID-19) outbreak on the Diamond Princess ship using the public surveillance data from January 20 to February 20, 2020. *medRxiv*. 2020:2020.02.26.20028449.
    
    

13. 13.Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–286. doi:10.1007/s12098-020-03263-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s12098-020-03263-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

14. 14.How do case fatality rates from COVID-19 compare to those of the seasonal flu?. 2020. Available at: [https://ourworldindata.org/coronavirus](https://ourworldindata.org/coronavirus) Access Apr, 2020.
    
    

15. 15.Coronavirus disease 2019 (COVID-19) Situation Report—30. 2020. Available at: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200219-sitrep-30-covid-19.pdf?sfvrsn=3346b04f_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200219-sitrep-30-covid-19.pdf?sfvrsn=3346b04f_2) Access Mar, 2020.
    
    

16. 16.Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Feb 21.
    
    

17. 17.Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, et al. Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions. Journal of clinical medicine. 2020 Feb 7;9(2). PubMed PMID: 32046137. Epub 2020/02/13. eng.
    
    

18. 18.Tang B, Xia F, Bragazzi NL, Wang X, He S, Sun X, et al. Lessons drawn from China and South Korea for managing COVID-19 epidemic: insights from a comparative modeling study. medRxiv. 2020.
    
    

19. 19.Ahmadi A, Shirani M, Rahmani F. Modeling and Forecasting Trend of COVID-19 Epidemic in Iran. medRxiv. 2020:2020.03.17.20037671.
    
    

20. 20.Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. The Lancet Digital Health. 2020.
    
    

21. 21.Tang S, Tang B, Bragazzi NL, Xia F, Li T, He S, et al. Stochastic discrete epidemic modeling of COVID-19 transmission in the Province of Shaanxi incorporating public health intervention and case importation. medRxiv. 2020.
    
    

22. 22.Tariq A, Lee Y, Roosa K, Blumberg S, Yan P, Ma S, et al. Real-time monitoring the transmission potential of COVID-19 in Singapore, February 2020. medRxiv. 2020.
    
    

23. 23.Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. Journal of Infection. 2020.
    
    

24. 24.Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19. medRxiv. 2020:2020.03.03.20029983.
    
    

25. 25.Tuite AR, Fisman DN. Reporting, Epidemic Growth, and Reproduction Numbers for the 2019 Novel Coronavirus (2019-nCoV) Epidemic. Annals of Internal Medicine. 2020.
    
    

26. 26.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.1585&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

27. 27.Wang M, Qi J. A deterministic epidemic model for the emergence of COVID-19 in China. medRxiv. 2020.
    
    

28. 28.Wang W, Chen Y, Wang Q, Cai P, He Y, Hu S, et al. The Transmission Dynamics of SARS-COV-2 in China: Modeling Study and the Impact of Public Health Interventions. Available at SSRN 3551319. 2020.
    
    

29. 29.Wang Y, You X, Wang Y, Peng L, Du Z, Gilmour S, et al. Estimating the basic reproduction number of COVID-19 in Wuhan, China. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi. 2020;41(4):476.
    
    

30. 30.Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020;26(4):506–10.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-020-0822-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

31. 31.Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020.
    
    

32. 32.Wu P, Hao XX, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020;25(3):4–9.
    
    

33. 33.Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2020.
    
    

34. 34.Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj-British Medical Journal. 2020;368.
    
    

35. 35.Yang S, Cao P, Du P, Wu Z, Zhuang Z, Yang L, et al. Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis. Annals of translational medicine. 2020;8(4):128.
    
    

36. 36.You C, Deng Y, Hu W, Sun J, Lin Q, Zhou F, et al. Estimation of the Time-Varying Reproduction Number of COVID-19 Outbreak in China. Available at SSRN 3539694. 2020.
    
    

37. 37.Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. The Journal of infectious diseases. 2020.
    
    

38. 38.Zhan C, Tse CK, Lai Z, Hao T, Su J. Prediction of COVID-19 Spreading Profiles in South Korea, Italy and Iran by Data-Driven Coding. medRxiv. 2020:2020.03.08.20032847.
    
    

39. 39.Zhang B, Zhou H, Zhou F. Study on SARS-COV-2 transmission and the effects of control measures in China. medRxiv. 2020:2020.02.16.20023770.
    
    

40. 40.zhang l, wan k, chen j, lu c, dong l, wu z. When will the battle against novel coronavirus end in Wuhan: a SEIR modeling analysis. medRxiv. 2020:2020.02.16.20023804.
    
    

41. 41.Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of Novel Coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis. International Journal of Infectious Diseases. 2020.
    
    

42. 42.Zhanwei D, Xiaoke X, Ye W, Lin W, Benjamin JC, Lauren Ancel M. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerging Infectious Disease journal. 2020;26(6).
    
    

43. 43.Zhao H, Man S, Wang B, Ning Y. Epidemic size of novel coronavirus-infected pneumonia in the Epicenter Wuhan: using data of five-countries’ evacuation action. medRxiv. 2020:2020.02.12.20022285.
    
    

44. 44.Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. International Journal of Infectious Diseases. 2020; 92: 214–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijid.2020.01.050&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32007643&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

45. 45.Zhao S, Musa SS, Lin Q, Ran J, Yang G, Wang W, et al. Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. Journal of clinical medicine. 2020;9(2).
    
    

46. 46.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet.
    
    

47. 47.Zhou G, Chi C. A model simulation study on effects of intervention measures in Wuhan COVID-19 epidemic. medRxiv. 2020:2020.02.14.20023168.
    
    

48. 48.Zhou T, Liu Q, Yang Z, Liao J, Yang K, Bai W, et al. Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV. Journal of Evidence-Based Medicine. 2020.
    
    

49. 49.Anastassopoulou C, Russo L, Tsakris A, Siettos C. Data-Based Analysis, Modelling and Forecasting of the novel Coronavirus (2019-nCoV) outbreak. *medRxiv*. 2020.
    
    

50. 50.Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Eurosurveillance. 2020;25(5):10–5.
    
    

51. 51.Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. The Lancet Infectious Diseases.
    
    

52. 52.Cao Z, Zhang Q, Lu X, Pfeiffer D, Jia Z, Song H, et al. Estimating the effective reproduction number of the 2019-nCoV in China. *medRxiv*. 2020:2020.01.27.20018952.
    
    

53. 53.Chen TM, Rui J, Wang QP, Zhao ZY, Cui JA, Yin L. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infectious diseases of poverty. 2020;9(1):24.
    
    

54. 54.Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak. *medRxiv*. 2020:2020.02.09.20021261.
    
    

55. 55.Chong YC. A Novel Method for the Estimation of a Dynamic Effective Reproduction Number (Dynamic-R) in the CoViD-19 Outbreak. medRxiv. 2020.
    
    

56. 56.Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: Severity of 2019-novel coronavirus (nCoV). Imperial College, Febbario. 2020.
    
    

57. 57.Kretzschmar ME, Rozhnova G, van Boven ME. Effectiveness of isolation and contact tracing for containment and slowing down a COVID-19 epidemic: a modelling study. medRxiv. 2020.
    
    

58. 58.Kuniya T. Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. Journal of clinical medicine. 2020;9(3).
    
    

59. 59.Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early Phylogenetic Estimate of the Effective Reproduction Number Of 2019-nCoV. medRxiv. 2020.
    
    

60. 60.Lau H, Khosrawipour V, Kocbach P, Mikolajczyk A, Schubert J, Bania J, et al. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. Journal of travel medicine. 2020.
    
    

61. 61.Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020.
    
    

62. 62.Leung C. The difference in the incubation period of 2019 novel coronavirus (SARS-CoV-2) infection between travelers to Hubei and non-travelers: The need of a longer quarantine period. Infection Control & Hospital Epidemiology. 1–8.
    
    

63. 63.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine. 2020.
    
    

64. 64.Li XG, Wang W, Zhao XF, Zai JJ, Zhao Q, Li Y, et al. Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol.
    
    

65. 65.Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, et al. Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. medRxiv. 2020.
    
    

66. 66.Lin Q, Hu T, Zhou X-H. Estimating the daily trend in the size of the COVID-19 infected population in Wuhan. medRxiv. 2020:2020.02.12.20022277.
    
    

67. 67.Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. Journal of clinical medicine. 2020;9(2).
    
    

68. 68.Liu T, Hu J, Xiao J, He G, Kang M, Rong Z, et al. Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. bioRxiv. 2020.
    
    

69. 69.Mizumoto K, Kagaya K, Chowell G. Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City: China, January-February, 2020. *medRxiv*. 2020:2020.02.12.20022434.
    
    

70. 70.Muniz-Rodriguez K, Fung IC-H, Ferdosi SR, Ofori SK, Lee Y, Tariq A, et al. Transmission potential of COVID-19 in Iran. medRxiv. 2020:2020.03.08.20030643.
    
    

71. 71.Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Kinoshita R, et al. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights. Journal of clinical medicine. 2020;9(2).
    
    

72. 72.Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. International Journal of Infectious Diseases. 2020.
    
    

73. 73.Omori R, Mizumoto K, Nishiura H. Ascertainment rate of novel coronavirus disease (COVID-19) in Japan. medRxiv. 2020:2020.03.09.20033183.
    
    

74. 74.Park SW, Bolker BM, Champredon D, Earn DJ, Li M, Weitz JS, et al. Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) outbreak. medRxiv. 2020.
    
    

75. 75.Peng L, Yang W, Zhang D, Zhuge C, Hong L. Epidemic analysis of COVID-19 in China by dynamical modeling. arXiv preprint arXiv:200206563. 2020.
    
    

76. 76.Pung R, Chiew CJ, Young BE, Chin S, Chen MI, Clapham HE, et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. The Lancet. 2020.
    
    

77. 77.Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM: monthly journal of the Association of Physicians. 2020.
    
    

78. 78.Rabajante JF. Insights from early mathematical models of 2019-nCoV acute respiratory disease (COVID-19) dynamics. arXiv preprint arXiv:200205296. 2020.
    
    

79. 79.Read JM, Bridgen JR, Cummings DA, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. *medRxiv*. 2020:2020.01.23.20018549.
    
    

80. 80.Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(4).
    
    

81. 81.Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. The Novel Coronavirus, 2019-nCoV, is Highly Contagious and More Infectious Than Initially Estimated. *medRxiv*. 2020:2020.02.07.20021154.
    
    

82. 82.Shen M, Peng Z, Xiao Y, Zhang L. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. *bioRxiv*. 2020.
    
    

83. 83.Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. International Journal of Infectious Diseases. 2020.
    
    

84. 84.Fang Y, Nie Y, Penny M. Transmission dynamics of the COVID-19 outbreak and effectiveness of government interventions: A data-driven analysis. J Med Virol.n/a(n/a).
    
    

85. 85.Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation interval for COVID-19 based on symptom onset data. medRxiv. 2020:2020.03.05.20031815.
    
    

86. 86.Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine. 2020.
    
    

87. 87.Hermanowicz SW. Forecasting the Wuhan coronavirus (2019-nCoV) epidemics using a simple (simplistic) model. *medRxiv*. 2020.
    
    

88. 88.Hu ZL, Song C, Xu CJ, Jin GF, Chen YL, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Science China-Life Sciences.
    
    

89. 89.Jiang X, Rayner S, Luo MH. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med Virol. 2020;92(5):476–8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.25708&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

90. 90.Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases. Journal of clinical medicine. 2020;9(2).
    
    

91. 91.Ki M. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiology and health. 2020; 42:e2020007.
    
    

92. 92.Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.25689&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

93. 93.White LF, Wallinga J, Finelli L, Reed C, Riley S, Lipsitch M, et al. Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza and other respiratory viruses. 2009;3(6):267–76.
    
    

94. 94.Bettencourt LM, Ribeiro RM. Real time bayesian estimation of the epidemic potential of emerging infectious diseases. PLoS One. 2008;3(5).
    
    

95. 95.Obadia T, Haneef R, Boëlle P-Y. The R0 package: a toolbox to estimate reproduction numbers for epidemic outbreaks. BMC medical informatics and decision making. 2012;12(1):147.
    
    

96. 96.Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. The Lancet. 2003;361(9371):1761–6.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 

97. 97.Majumder MS, Rivers C, Lofgren E, Fisman D. Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLoS Currents. 2014;6.
    
    

98. 98.Ghani A, Donnelly C, Cox D, Griffin J, Fraser C, Lam T, et al. Methods for estimating the case fatality ratio for a novel, emerging infectious disease. American journal of epidemiology. 2005;162(5):479–86.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/aje/kwi230&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16076827&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F05%2F06%2F2020.05.02.20088385.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000231363800012&link_type=ISI) 

99. 99.Rahmanian V, Rabiee MH, Sharifi H. Case fatality rate of coronavirus disease 2019 (COVID-19) in Iran-a term of caution. 2020.
    
    

100.100.Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine. 2020.
    
    

101.101.Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging infectious diseases. 2020;26(7).
    
    

102.102.Muniz-Rodriguez K, Fung IC-H, Ferdosi SR, Ofori SK, Lee Y, Tariq A, et al. Transmission potential of COVID-19 in Iran. medRxiv. 2020:2020.03.08.20030643.
    
    

103.103.Kretzschmar ME, Rozhnova G, van Boven ME. Effectiveness of isolation and contact tracing for containment and slowing down a COVID-19 epidemic: a modelling study. medRxiv. 2020.